Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30254817 | 1.00 | ATM (0.31) | ATMMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29674976 | 0.89 | ATM (0.35) | ATMMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL436483 | 0.89 | ATM (0.35) | ATMMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7945423 | 0.89 | ATM (0.35) | ATMMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL30338525 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL29923024 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL566021 | 0.81 | ATM (0.31) | ATM | |
| Hydrochloric Acid SCHEMBL29690902 | 0.80 | CES2 (0.32) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL437960 | 0.76 | MEN1 (0.35) | ATMMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7947296 | 0.76 | MEN1 (0.35) | ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624220-B2 | Composition and cured product thereof | DENKA COMPANY LIMITED (JP) | 2026-05-12 | — | — | US | disclosed |
| EP-4723139-A2 | COMPOSITION AND CURED BODY | Denka Company Limited (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4183843-B1 | COMPOSITION AND CURED BODY | DENKA COMPANY LTD (JP) | 2026-03-11 | — | — | EP | disclosed |
| CN-121586742-A | Uncured sheet and cured body thereof | 电化株式会社 | 2026-02-27 | — | — | CN | disclosed |
| EP-4644439-A1 | COPOLYMER, PRODUCING METHOD FOR SAME, AND CURED BODY CONTAINING COPOLYMER | Denka Company Limited (JP) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025075056-A1 | COMPOSITION AND CURED PRODUCT THEREOF | デンカ株式会社 | 2025-04-10 | — | — | WO | disclosed |
| WO-2025041755-A1 | COMPOSITION, MOLDED BODY AND CURED BODY, AND LAMINATE | デンカ株式会社 | 2025-02-27 | — | — | WO | disclosed |
| WO-2025028516-A1 | UNCURED SHEET AND CURED BODY OF SAME | デンカ株式会社 | 2025-02-06 | — | — | WO | disclosed |
| CN-119343387-A | Varnish and cured product thereof | 电化株式会社 | 2025-01-21 | — | — | CN | disclosed |
| CN-118599040-A | Composition and cured body | 电化株式会社 | 2024-09-06 | — | — | CN | disclosed |
| CN-118599041-A | Composition and cured body | 电化株式会社 | 2024-09-06 | — | — | CN | disclosed |
| WO-2024143509-A1 | COPOLYMER, PRODUCING METHOD FOR SAME, AND CURED BODY CONTAINING COPOLYMER | デンカ株式会社 | 2024-07-04 | — | — | WO | disclosed |
| CN-115698200-B | Composition and cured body | 电化株式会社 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024014436-A1 | VARNISH AND CURED BODY THEREOF | デンカ株式会社 | 2024-01-18 | — | — | WO | disclosed |
| US-20230287222-A1 | COMPOSITION AND CURED PRODUCT THEREOF | DENKA COMPANY LIMITED (JP) | 2023-09-14 | — | — | US | disclosed |
| CN-115698200-A | Composition and cured body | 电化株式会社 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624220-B2 | Composition and cured product thereof | VCL, PCNA, PUF60 | ATM 3784/4885MEN1 3516/4885KMT2A 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.